Investigating started sample size, completed sample size and drop‐out rate in 10 252 phase III clinical trials: Insights from ClinicalTrials.gov

Documenti analoghi

• Transgender people in clinical trials of drugs and biologics: An analysis of ClinicalTrials.gov from 2007 to 2023
  di: Zachary Schonrock, et al.
  Pubblicazione: (2024)
• Randomization in phase II trials: No exemption based on sample size
  di: Theodor Framke, et al.
  Pubblicazione: (2025)
• The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview
  di: Elise Le Flohic, et al.
  Pubblicazione: (2024)
• Spotlight commentary: Innovations in clinical trials
  di: Nataša Hudej, et al.
  Pubblicazione: (2025)
• Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’
  di: Tamás Ágh, et al.
  Pubblicazione: (2025)